Kymera Therapeutics reported net income of -$139.58M for the quarter ended Sep 2026. This income statement covers 29 quarters of results from Sep 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 | Sep2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||||||
| Revenue | 15.28M | 9.62M | 11.51M | 9.55M | 16.14M | 9.47M | 16.51M | 4.73M | 47.89M | 10.29M | 25.65M | 3.74M | 7.39M | 22.10M | 11.48M | 2.76M | 2.87M | 34.37M | 65.00M | ||||||||||
| Operating items | |||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 37.53M | 35.94M | 41.29M | 43.88M | 43.13M | 42.23M | 45.77M | 48.12M | 52.97M | 48.82M | 59.20M | 60.41M | 71.82M | 80.26M | 78.39M | 74.09M | 83.83M | 98.16M | 119.48M | 128.51M | |||||||||
| Selling, General & AdministrativeSG&A | 11.74M | 10.61M | 11.03M | 10.56M | 11.64M | 12.57M | 14.13M | 14.12M | 14.23M | 14.37M | 17.37M | 15.46M | 16.33M | 16.27M | 17.65M | 17.34M | 16.94M | 20.36M | 21.13M | 18.72M | |||||||||
| Other Operating ExpensesOther Opex | 4.93M | 3.86M | |||||||||||||||||||||||||||
| Operating ExpensesOpex | 49.27M | 46.56M | 52.32M | 54.43M | 54.77M | 54.79M | 59.90M | 62.24M | 67.20M | 68.12M | 76.58M | 75.87M | 88.15M | 96.53M | 96.03M | 95.29M | 100.77M | 118.52M | 140.61M | 147.23M | |||||||||
| Operating IncomeOp. Inc | -33.99M | -36.93M | -40.81M | -44.88M | -38.63M | -45.33M | -43.38M | -57.51M | -19.31M | -57.83M | -50.93M | -72.12M | -80.76M | -74.43M | -84.56M | -92.52M | -97.90M | -84.15M | -75.61M | -147.23M | |||||||||
| Non-operating items | |||||||||||||||||||||||||||||
| Non Operating Interest Expenses | -0.05M | -0.04M | -0.04M | -0.04M | -0.06M | -0.06M | -0.05M | -0.04M | -0.05M | -0.07M | -0.06M | -0.06M | -0.06M | -0.07M | -0.11M | -0.10M | -0.09M | -0.06M | -0.08M | -0.06M | |||||||||
| Goodwill impairment chargesGoodwill Impair. | 4.93M | 3.86M | |||||||||||||||||||||||||||
| Gains (Losses) on Sale of Assets & InvestmentsGains on Sales | -0.51M | -2.56M | -0.77M | -1.93M | 0.96M | 1.91M | -0.60M | 1.19M | 1.90M | -1.23M | -0.32M | 4.03M | -3.42M | 1.43M | 0.34M | 1.22M | 0.30M | -5.99M | -2.96M | -7.58M | |||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.15M | 0.29M | 0.59M | 1.92M | 3.82M | 4.45M | 4.63M | 4.68M | 5.00M | 9.34M | 8.92M | 9.70M | 10.06M | 8.92M | 8.05M | 10.44M | 11.01M | 14.98M | 14.48M | 15.30M | |||||||||
| Non Operating IncomeNon Op. Inc. | 0.09M | 0.25M | 0.55M | 1.88M | 3.77M | 4.40M | 4.58M | 4.64M | 4.94M | 9.27M | 8.86M | 9.64M | 10.00M | 8.85M | 7.94M | 10.35M | 10.92M | 14.92M | 14.40M | 15.23M | |||||||||
| Net income details | |||||||||||||||||||||||||||||
| EBIT | -33.99M | -36.93M | -40.81M | -44.88M | -38.63M | -45.33M | -43.38M | -57.51M | -19.31M | -57.83M | -50.93M | -72.12M | -80.76M | -74.43M | -84.56M | -92.52M | -97.90M | -84.15M | -75.61M | -147.23M | |||||||||
| EBT | -33.94M | -36.89M | -40.77M | -44.85M | -38.57M | -45.27M | -43.34M | -57.47M | -19.26M | -57.76M | -50.86M | -72.06M | -80.70M | -74.35M | -84.45M | -92.42M | -97.81M | -84.09M | -75.53M | -147.17M | |||||||||
| Income After Tax | -33.94M | -36.89M | -40.77M | -44.85M | -38.57M | -45.27M | -43.34M | -57.47M | -19.26M | -57.76M | -50.86M | -72.06M | -80.70M | -74.35M | -84.45M | -92.42M | -97.81M | -84.09M | -75.53M | -147.17M | |||||||||
| Income from Continuing OperationsIncome (Continuing) | -33.94M | -36.89M | -40.77M | -44.85M | -38.57M | -45.27M | -43.34M | -57.47M | -19.26M | -57.76M | -50.86M | -72.06M | -80.70M | -74.35M | -84.45M | -92.42M | -97.81M | -84.09M | -75.53M | -147.17M | |||||||||
| Consolidated Net IncomeConsol Net Inc. | -34.41M | -39.24M | -41.02M | -44.93M | -33.90M | -39.02M | -39.40M | -51.68M | -12.47M | -49.78M | -42.38M | -58.46M | -74.17M | -64.15M | -76.28M | -80.95M | -86.68M | -75.23M | -64.17M | -139.58M | |||||||||
| Income towards Parent CompanyParent Net Inc | -33.90M | -36.68M | -40.26M | -43.00M | -34.87M | -40.93M | -38.80M | -52.87M | -14.37M | -48.56M | -42.06M | -62.49M | -70.75M | -65.58M | -76.61M | -82.18M | -86.98M | -69.23M | -61.21M | -132.00M | |||||||||
| Preferred Dividend PaymentsPref Dividends | |||||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -33.90M | -36.68M | -40.26M | -43.00M | -34.87M | -40.93M | -38.80M | -52.87M | -14.37M | -48.56M | -42.06M | -62.49M | -70.75M | -65.58M | -76.61M | -82.18M | -86.98M | -69.23M | -61.21M | -132.00M | |||||||||
| Additional items | |||||||||||||||||||||||||||||
| EPS (Basic) | -0.71 | -0.71 | -0.78 | -0.79 | -0.65 | -0.70 | -0.67 | -0.90 | -0.25 | -0.69 | -0.58 | -0.82 | -0.94 | -0.82 | -0.95 | -0.94 | -1.03 | -0.71 | -0.62 | -1.32 | |||||||||
| EPS (Diluted) | -0.71 | -0.71 | -0.78 | -0.79 | -0.65 | -0.70 | -0.67 | -0.90 | -0.25 | -0.69 | -0.58 | -0.82 | -0.94 | -0.82 | -0.95 | -0.94 | -1.03 | -0.71 | -0.62 | -1.32 | |||||||||
| Shares Outstanding | 47.99M | 51.65M | 51.77M | 54.54M | 53.93M | 58.19M | 58.33M | 58.42M | 58.37M | 70.77M | 73.06M | 76.13M | 75.04M | 80.15M | 80.45M | 87.30M | 84.49M | 97.53M | 98.18M | 100.10M | |||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 47.99M | 51.65M | 51.77M | 54.54M | 53.93M | 58.19M | 58.33M | 58.42M | 58.37M | 70.77M | 73.06M | 76.13M | 75.04M | 80.15M | 80.45M | 87.30M | 84.49M | 97.53M | 98.18M | 100.10M | |||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 51.54M | 51.69M | 51.85M | 54.75M | 55.04M | 55.28M | 55.39M | 55.45M | 55.59M | 61.35M | 61.57M | 64.75M | 64.89M | 65.11M | 70.56M | 71.74M | 81.32M | 82.18M | 82.79M | 85.33M | |||||||||
| EBITDA | -33.31M | -36.25M | -40.11M | -44.12M | -37.81M | -44.45M | -42.48M | -56.61M | -18.42M | -56.37M | -48.99M | -70.14M | -78.77M | -72.38M | -82.47M | -90.37M | -95.86M | -82.13M | -73.58M | -145.21M | |||||||||
| Interest ExpensesInt Expense | -0.05M | -0.04M | -0.04M | -0.04M | -0.06M | -0.06M | -0.05M | -0.04M | -0.05M | -0.07M | -0.06M | -0.06M | -0.06M | -0.07M | -0.11M | -0.10M | -0.09M | -0.06M | -0.08M | -0.06M |
Pull Kymera Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=KYMR&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "KYMR", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=KYMR&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();